427 results on '"Symmans, W. Fraser"'
Search Results
2. Simple combination of multiple somatic variant callers to increase accuracy
3. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”
4. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer
5. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy
6. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series
7. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy: Recommendations From the I-SPY Pathology Working Group
8. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial
9. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
10. Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer
11. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
12. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
13. Molecular testing opportunities on cytology effusion specimens: the pre-analytic effects of various body fluid cytology preparation methods on RNA extraction quality and targeted sequencing
14. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
15. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
16. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer
17. Hormonal modulation of ESR1 mutant metastasis
18. Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples
19. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
20. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
21. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update
22. Challenges and Gaps in Clinical Trial Genomic Data Management
23. Correction to: Hormonal modulation of ESR1 mutant metastasis
24. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
25. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
26. Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer
27. Microtubule-Associated Protein Tau: A Marker of Paclitaxel Sensitivity in Breast Cancer
28. The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues
29. Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
30. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
31. Pre‐analytical effects on whole transcriptome and targeted RNA sequencing analysis in cytology: The effects of prolonged time in storage of effusion specimens prior to preservation.
32. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
33. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy
34. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy
35. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.
36. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.
37. Residual Cancer Burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multi-center pooled analysis of 5161 patients
38. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers
39. HER2 testing in patients with breast cancer: Must be performed in a timely manner to facilitate appropriate treatment decisions
40. Uncertainty estimation with a finite dataset in the assessment of classification models
41. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor—positive breast cancer
42. Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers
43. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers
44. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
45. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials
46. Changes in Nurse Cell Nuclei during Synchronous Infection with Trichinella spiralis
47. A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories
48. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
49. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
50. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.